Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria
Por:
Camps-Vilaro, A, Delgado-Jimenez, JF, Farre, N, Tizon-Marcos, H, Alvarez-Garcia, J, Cinca, J, Degano, IR, Marrugat, J
Publicada:
1 jul 2020
Resumen:
Heart failure (HF) is one of the main causes of morbidity, mortality, and high healthcare costs. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced cardiovascular mortality and hospitalization for HF compared to placebo in patients with chronic HF, and reduced ejection fraction (EF) in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study. Our aim was to estimate the number of patients with DAPA-HF characteristics in Spain. Our literature review identified epidemiological studies whose objective was to quantify the prevalence of HF and its comorbidities in Spain. We estimated the prevalence of HF with reduced EF, of New York Heart Association (NYHA) functional class II-IV, and with a glomerular filtration rate (GFR) >= 30 mL/min/1.73 m(2). In this population, we analysed the prevalence of diabetes using data from the REDINSCOR (Spanish Network for Heart Failure) registry. Our estimations indicate there are 594,684 patients >= 45 years old with HF in Spain (2.6% of this population age group), of which 52.4%, 84.0%, and 93.9% have reduced EF, are NYHA II-IV, and have a GFR >= 30 mL/min/1.73 m(2), respectively. By our calculations, approximately 245,789 Spanish patients would meet the DAPA-HF patient profile, and therefore could benefit from the protective cardiovascular effects of dapagliflozin.
Filiaciones:
Camps-Vilaro, A:
IMIM Hosp del Mar Med Res Inst, REGICOR Study Grp, Barcelona 08003, Spain
Inst Salud Carlos III ISCIII, CIBER Cardiovasc Dis CIBERCV, Madrid 28029, Spain
Delgado-Jimenez, JF:
Inst Salud Carlos III ISCIII, CIBER Cardiovasc Dis CIBERCV, Madrid 28029, Spain
Hosp Univ 12 Octubre, Dept Cardiol, Madrid 28041, Spain
Complutense Univ Madrid UCM, Fac Med, Madrid 28040, Spain
Farre, N:
Hosp del Mar, Dept Cardiol, Barcelona 08003, Spain
IMIM Hosp del Mar Med Res Inst, Heart Dis Biomed Res Grp GREC, Barcelona 08003, Spain
Univ Autonoma Barcelona UAB, Fac Med, Barcelona 08193, Spain
Tizon-Marcos, H:
Hosp del Mar, Dept Cardiol, Barcelona 08003, Spain
IMIM Hosp del Mar Med Res Inst, Heart Dis Biomed Res Grp GREC, Barcelona 08003, Spain
Alvarez-Garcia, J:
Inst Salud Carlos III ISCIII, CIBER Cardiovasc Dis CIBERCV, Madrid 28029, Spain
Univ Autonoma Barcelona UAB, Fac Med, Barcelona 08193, Spain
Hosp Santa Creu & Sant Pau, Dept Cardiol, Barcelona 08041, Spain
Cinca, J:
Inst Salud Carlos III ISCIII, CIBER Cardiovasc Dis CIBERCV, Madrid 28029, Spain
Univ Autonoma Barcelona UAB, Fac Med, Barcelona 08193, Spain
Hosp Santa Creu & Sant Pau, Dept Cardiol, Barcelona 08041, Spain
Degano, IR:
IMIM Hosp del Mar Med Res Inst, REGICOR Study Grp, Barcelona 08003, Spain
Inst Salud Carlos III ISCIII, CIBER Cardiovasc Dis CIBERCV, Madrid 28029, Spain
Univ Vic Cent Univ Catalonia UVic UCC, Fac Med, Vic 08500, Spain
Marrugat, J:
IMIM Hosp del Mar Med Res Inst, REGICOR Study Grp, Barcelona 08003, Spain
Inst Salud Carlos III ISCIII, CIBER Cardiovasc Dis CIBERCV, Madrid 28029, Spain
Green Published, gold
|